1. Cystic fibrosis foundation pulmonary guidelines. Use of cystic fibrosis transmembrane conductance regulator modulator therapy in patients with cystic fibrosis;Ren;Ann Am Thorac Soc,2018
2. Kaftrio (iwacaftor, tezacaftor, elexsacaftor) Summary of Product Characteristics Updated 21-Apr-2023. Vertex Pharmaceuticals (Europe) Limited https://www.medicines.org.uk/emc/product/13216/smpc.
3. Acute liver failure in a patient with cystic fibrosis taking triple combination modulator;Sharma;ATS Conference 2021 American Journal of Respiratory and Critical Care Medicine,2021
4. Hope in every breath: navigating the therapeutic landscape of cystic fibrosis;Sreenivasulu;Cereus,2023
5. Longitudinal study of therapeutic adherence in a cystic fibrosis unit: identifying potential factors associated with medication possession ratio;Girón;Antibiotics,2022